Related Experiment Video
Updated: Dec 31, 2025

Cecal Ligation Puncture Procedure
Published on: May 7, 2011
Hypofibrinolysis induced by tranexamic acid does not influence inflammation and mortality in a polymicrobial sepsis
Yzabella Alves Campos Nogueira1, Loredana Nilkenes Gomes da Costa1,2, Carlos Emilio Levy1
1School of Medical Sciences, University of Campinas, Campinas, SP, Brazil.
Abstract:
The biological relevance of fibrinolysis to the host response to sepsis is illustrated by pathogens such as S. pyogenes and Y. pestis, whose virulence factors are proteins that challenge the balance between pro- and anti-fibrinolytic factors of the host, and by the consistent finding of hypofibrinolysis in the early stages of sepsis. Whether this hypofibrinolytic response is beneficial or detrimental to the host, by containing the spread of pathogens while at the same time limiting the access of immune cell to infectious foci, is still a matter of debate. Tranexamic acid (TnxAc) is an antifibrinolytic agent that is being increasingly used to prevent and control bleeding in conditions such as elective orthopedic surgery, trauma, and post-partum-hemorrhage, which are frequently followed by infection and sepsis. Here we used a model of polymicrobial sepsis to evaluate whether hypofibrinolysis induced by TnxAc influenced survival, tissue injury and pathogen spread. Mice were treated with two doses of TnxAc bid for 48h, and then sepsis was induced by cecal ligation and puncture. Despite the induction of hypofibrinolysis by TnxAc, no difference could be observed in survival, tissue injury (measured by biochemical and histological parameters), cytokine levels or pathogen spread. Our results contribute with a new piece of data to the understanding of the complex interplay between fibrinolysis and innate immunity. While our results do not support the use of TnxAc in sepsis, they also address the thrombotic safety of TnxAc, a low cost and widely used agent to prevent bleeding.
Insights
Tranexamic acid (TnxAc), an antifibrinolytic, did not improve survival or reduce injury in a sepsis model. This study suggests TnxAc is not beneficial for sepsis and addresses its thrombotic safety in this context.
Area of Science:
- Immunology
- Infectious Diseases
- Hematology
Background:
- Fibrinolysis plays a role in the host response to sepsis, with pathogens challenging the host's pro- and anti-fibrinolytic balance.
- Early sepsis stages often show hypofibrinolysis, but its benefit or detriment to the host remains debated.
- Tranexamic acid (TnxAc), an antifibrinolytic, is used for bleeding but sepsis often follows procedures where it's administered.
Purpose of the Study:
- To investigate the impact of TnxAc-induced hypofibrinolysis on survival, tissue injury, and pathogen spread in a polymicrobial sepsis model.
- To assess the potential benefits or risks of using TnxAc in sepsis.
- To contribute data on the interplay between fibrinolysis and innate immunity.
Main Methods:
- A polymicrobial sepsis model was established in mice using cecal ligation and puncture.
- Mice received two doses of TnxAc twice daily for 48 hours before sepsis induction.
- Survival, tissue injury (biochemical and histological), cytokine levels, and pathogen spread were evaluated.
Main Results:
- TnxAc successfully induced hypofibrinolysis in the sepsis model.
- No significant differences were observed in survival rates between TnxAc-treated and control groups.
- Tissue injury, cytokine levels, and pathogen spread remained unchanged by TnxAc treatment.
Conclusions:
- TnxAc-induced hypofibrinolysis did not improve outcomes in this polymicrobial sepsis model.
- The findings do not support the use of TnxAc for treating sepsis.
- The study provides data on the thrombotic safety of TnxAc, a widely used antifibrinolytic agent.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis

